Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring
- PMID: 30373408
- DOI: 10.1080/10641963.2018.1529778
Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring
Abstract
Decrease in blood pressure contributes to the reno-protective effects of sodium-glucose cotransporter 2 inhibitors; however, its relationship with home monitoring of blood pressure is unclear. We retrospectively analyzed 101 visiting members of the Kanagawa Physicians Association with type 2 diabetes mellitus and chronic kidney disease who were taking sodium-glucose cotransporter 2 inhibitors and who monitored blood pressure at home for a median treatment period of 14 months. At baseline, the mean value of HbA1c was 59.3 mmol/mol (7.6%) and the median value of albumin-creatinine ratio was 30.9 mg/gCr that was evaluated in 88 patients. The mean blood pressure both at office and home significantly decreased, and there was a significant positive correlation between the change in albumin-creatinine ratio and both blood pressures. Controlled hypertension, masked hypertension, white coat hypertension, and sustained hypertension were observed in 10.9%, 13.9%, 12.9%, and 62.4% of patients at the initiation of therapy, which changed to 10.9%, 16.8%, 17.8%, and 54.5% at the time of the survey, respectively. In conclusion, management of blood pressure both at office and home was found to be important for the reno-protective effects of sodium-glucose cotransporter 2 inhibitors along with strict blood pressure management.
Keywords: Sodium glucose co-transporter 2 inhibitors; albumin-creatinine ratio; chronic kidney disease; home blood pressure monitoring; masked hypertension.
Similar articles
-
Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease.J Diabetes Res. 2019 Nov 3;2019:9415313. doi: 10.1155/2019/9415313. eCollection 2019. J Diabetes Res. 2019. PMID: 31781668 Free PMC article.
-
The influence of long-term administration of SGLT2 inhibitors on blood pressure at the office and at home in patients with type 2 diabetes mellitus and chronic kidney disease.J Clin Hypertens (Greenwich). 2020 Dec;22(12):2306-2314. doi: 10.1111/jch.14084. Epub 2020 Oct 21. J Clin Hypertens (Greenwich). 2020. PMID: 33086437 Free PMC article.
-
Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.Diab Vasc Dis Res. 2019 Jan;16(1):103-107. doi: 10.1177/1479164118802759. Epub 2018 Oct 4. Diab Vasc Dis Res. 2019. PMID: 30284913
-
Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease.Front Endocrinol (Lausanne). 2023 Dec 20;14:1281107. doi: 10.3389/fendo.2023.1281107. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38174341 Free PMC article. Review.
-
Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.Vasc Health Risk Manag. 2016 Oct 27;12:393-405. doi: 10.2147/VHRM.S111991. eCollection 2016. Vasc Health Risk Manag. 2016. PMID: 27822054 Free PMC article. Review.
Cited by
-
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.Front Pharmacol. 2024 Mar 27;15:1358573. doi: 10.3389/fphar.2024.1358573. eCollection 2024. Front Pharmacol. 2024. PMID: 38601470 Free PMC article.
-
Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease.J Diabetes Res. 2019 Nov 3;2019:9415313. doi: 10.1155/2019/9415313. eCollection 2019. J Diabetes Res. 2019. PMID: 31781668 Free PMC article.
-
The influence of long-term administration of SGLT2 inhibitors on blood pressure at the office and at home in patients with type 2 diabetes mellitus and chronic kidney disease.J Clin Hypertens (Greenwich). 2020 Dec;22(12):2306-2314. doi: 10.1111/jch.14084. Epub 2020 Oct 21. J Clin Hypertens (Greenwich). 2020. PMID: 33086437 Free PMC article.
-
The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.Cardiovasc Endocrinol Metab. 2023 Sep 28;12(4):e0292. doi: 10.1097/XCE.0000000000000292. eCollection 2023 Dec. Cardiovasc Endocrinol Metab. 2023. PMID: 37779602 Free PMC article.
-
Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan.J Diabetes Investig. 2021 Aug;12(8):1408-1416. doi: 10.1111/jdi.13491. Epub 2021 Feb 1. J Diabetes Investig. 2021. PMID: 33377605 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous